The Role of Insulin-Regulated Aminopeptidase in MHC Class I Antigen Presentation by Loredana Saveanu & Peter van Endert
REVIEW ARTICLE
published: 21 March 2012
doi: 10.3389/ﬁmmu.2012.00057
The role of insulin-regulated aminopeptidase in MHC class
I antigen presentation
Loredana Saveanu1,2* and Peter van Endert 1,2*
1 Institut National de la Santé et de le Recherche Médicale, Paris, France
2 Faculté de Médecine, Université Paris Descartes, Paris, France
Edited by:
Christian Kurts, Friedrich
Wilhelms-Universität Bonn, Germany
Reviewed by:
Hansjörg Schild, University Medical
Center of the Johannes
Gutenberg-University, Germany
Sven Burgdorf, Rheinische Friedrich
Wilhelms-Universität Bonn, Germany
*Correspondence:
Loredana Saveanu, Faculté de
Médecine, Université Paris
Descartes, Sorbonne Paris Cité,
75015 Paris, France.
e-mail: loredana.saveanu@inserm.fr;
Peter van Endert , Institut National de
la Santé et de le Recherche Médicale,
U1013, Paris 75015, France.
e-mail: peter.van-endert@inserm.fr
Production of MHC-I ligands from antigenic proteins generally requires multiple proteolytic
events. While the proteolytic steps required for antigen processing in the endogenous
pathway are clearly established, persisting gaps of knowledge regarding putative cross-
presentation compartments have made it difﬁcult to map the precise proteolytic events
required for generation of cross-presented antigens. It is only in the past decade that the
importance of aminoterminal trimming as the ﬁnal step in the endogenous presentation
pathway has been recognized and that the corresponding enzymes have been described.
This review focuses on the aminoterminal trimming of exogenous cross-presented pep-
tides, with particular emphasis on the identiﬁcation of insulin responsive aminopeptidase
(IRAP) as the principal trimming aminopeptidase in endosomes and phagosomes.
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HISTORY
Insulin responsive aminopeptidase (IRAP) was initially identiﬁed
due to its abundance in adipocytes, in specialized endosomes called
Glut4 storage vesicles (GSV). The discovery of the glucose trans-
porter Glut4 in 1989 (Birnbaum, 1989; James et al., 1989) was
followed by sustained efforts to identify the biochemical compo-
sition of GSV, which revealed an abundant protein with a MW of
around 160–165 kDa that was constantly associated with isolated
GSV and called vp 165. Finally, Keller et al. (1995) identiﬁed sev-
eral tryptic peptides from vp 165, designed oligonucleotide probes
based on these peptide sequences and succeeded in cloning full-
length IRAP cDNA from an adipose tissue cDNA library. Thus,
intracellular localization of IRAP in GSV was the basis for its
initial identiﬁcation. Analysis of IRAP in the context of the regu-
lation of glucose homeostasis has greatly advanced our knowledge
about the cellular biology of IRAP endosomes, which are recog-
nized as ubiquitous storage vesicles whose dynamics is regulated
by cell-speciﬁc stimuli. However, why an aminopeptidase activity
is present in GSV remains yet a mystery.
The situation was completely different for the second identiﬁ-
cation of the aminopeptidase, this time in the context of antigen
presentation. In the early 2000s, evidence about the requirement of
aminoterminal trimming of MHC class I ligand precursors accu-
mulated (Lauvau et al., 1999; Fruci et al., 2001; Serwold et al., 2001)
andprompted several laboratories, includingours, to search for the
enzymes performing this ﬁnal antigen-processing step. Searching
for aminopeptidase activities in fractionated protein extracts of
crude human B cell microsomes, we identiﬁed IRAP (Saveanu
et al., 2009) as well as ERAP1–ERAP2 complexes (Saveanu et al.,
2005b). The similarity between IRAP and the two ERAP proteins
and the co-puriﬁcation of MHC class I molecules with IRAP
suggested that the enzyme was involved in antigen presentation.
While the involvement of IRAP in endogenous presentation can
not be entirely ruled out, the experimental data available today
strongly support the conclusion that IRAP is required for trim-
ming of epitope precursors exclusively in MHC class I antigen
cross-presentation.
IRAP AS AMEMBER OF THEM1METALLOPEPTIDASE FAMILY
The genomic structure of the human IRAP gene (synonyms
LNPEP, oxytocinase, P-LAP) is very similar to the ERAP1 and
ERAP2 genes (Hattori et al., 2000; Rasmussen et al., 2000; Tan-
ioka et al., 2005). These three genes are located contiguously
on the human chromosome 5q15 suggesting the possibility of
their divergence from a common ancestral gene. Interestingly,
rodents have only two of these enzymes: IRAP (located on
murine chromosome 17) and ERAP1 (located on the murine
chromosome 13).
While both ER aminopeptidases are strongly induced by cell
exposure to interferon gamma (IFN-γ), IRAP protein levels do
not change upon IFN-γ stimulation. However, while the ERAP
genes have the features of house keeping genes without any TATA
or CAAT boxes, the IRAP gene is probably regulated during cell
differentiation. Studies performed on the 5′ untranslated region of
the IRAP gene in BeWo cells indicated that the transcription fac-
tors AP2 and Ikaros cooperatively up-regulate IRAP transcription
during differentiation into trophoblastic cells and directly bind to
the gene promoter (Iwanaga et al., 2003).
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The human IRAP gene codes for a type II transmembrane
protein with three domains: a cytoplasmic N-terminal domain
of 109-amino-acid, a transmembrane domain of 23-amino-acid,
and an intraluminal (or extracellular) domain of 893 amino acids,
which include 16 potential N-glycosylation sites (Keller et al.,
1995). The long C-terminal, intra-endosomal domain contains
a Zn-binding motif HEXXH(X)18E and the exopeptidase motif
GAMEN, which are encoded by exons 6 and 7. These two motifs
are also found in ERAP1 and ERAP2 and are shared by all mem-
bers of theM1 family of aminopeptidases (Tsujimoto andHattori,
2005).
The high percentage of protein sequence identity between IRAP
and ERAP1 or ERAP2 (43 or 49% identity, respectively), in cor-
relation with the phylogenetic analysis (Saveanu et al., 2005a)
indicates that these enzymes can be classiﬁed in a sub-family
of M1 aminopeptidases referred to, using an alternative designa-
tion of IRAP, “oxytocinase family” (Tsujimoto and Hattori, 2005).
The principal difference between the protein sequences of IRAP
and the other members of M1 metallopeptidase family, includ-
ing ERAP1 and 2, is the N-terminal cytoplasmic IRAP domain,
which is required for the enzyme localization and its complex
intracellular trafﬁcking (see below).
ENZYMATIC ACTIVITY AND NATURAL PEPTIDE SUBSTRATES
SYNTHETIC ANALOGS OF PEPTIDE SUBSTRATES
Several studies analyzed the substrate speciﬁcity of IRAP using ﬂu-
orogenic analogs of peptide substrates (e.g., aminoacyl 7-amino-
4-methylcoumarin; Saveanu et al., 2009; Georgiadou et al., 2010;
Zervoudi et al., 2011) and demonstrated that the enzyme removes
efﬁciently the followingN-terminal aminoacids: Cys,Arg,Lys,Leu,
Met, Tyr, Phe, Ala, and Gln. Although IRAP, ERAP1, and ERAP2
display substantial sequence identity and similarity, their substrate
speciﬁcity as measured using ﬂuorogenic substrates is quite differ-
ent. Interestingly, the substrate speciﬁcity of IRAP is very similar to
the speciﬁcity of the ERAP1–ERAP2 heterodimer with the differ-
ence that IRAP is active in a broader pH range than ERAPs.While
80% of maximal activity of IRAP is conserved at pH 5 or 8, ERAP1
preserved only 30% activity at these pH values (Georgiadou et al.,
2010). The functional role of the differences in substrate speciﬁcity
between IRAP and ERAPs will be discussed later.
HORMONES AND VASOACTIVE PEPTIDES ARE NATURAL IRAP
SUBSTRATES
Prior to its characterization as an epitope trimming aminopep-
tidase, IRAP has been described to inactivate several hormones,
vasoactive peptides, and neuropeptides such as oxytocin, somato-
statin, cholecystokinin, angiotensin III, Lys-bradikinin, vaso-
pressin, Met-and Leu-enkephalin, neurokinin A, and dynorphin
A (Tsujimoto et al., 1992; Herbst et al., 1997; Matsumoto et al.,
2001).
A soluble form of human IRAP (starting at residue Ala155)
can be detected in human serum during pregnancy. This form is
generated by shedding of IRAP from the cell membrane by mem-
bers of the ADAM (a disintegrin and metalloproteinase) family of
endopeptidases (Ito et al., 2004). Increased levels of soluble IRAP
in human serumduring pregnancy and the ability of IRAP to inac-
tivate the hormone oxytocin by cleavage between the N-terminal
cysteine and the adjacent tyrosine residue initially designated IRAP
as the enzyme regulating the oxytocin levels to prevent premature
delivery. However, it is likely that other serum enzymes can also
inactivate oxytocin since murine IRAP does not have the Phe154-
Ala155 sequence where cleavage occurs to produce the soluble
IRAPenzyme,and since IRAPdeﬁcientmice display normal repro-
ductive and maternal behavior (Pham et al., 2009). In support of
this conclusion, Keller’s group evaluated the oxytocin clearance
from the circulation of wt and IRAP deﬁcient mice and showed
that oxytocin is inactivated in vivo in the absence of IRAP (Wallis
et al., 2007). The same authors demonstrated that vasopressin is
cleaved in vivo exclusively by IRAP and found that IRAP deﬁcient
mice have a decreased vasopressin synthesis, probably due to a
negative feedback effect. In conclusion, until now, there is only
one peptide hormone identiﬁed as a speciﬁc substrate for IRAP
in vivo, vasopressin. A genetic study on patients undergoing septic
shock further suggested that inactivation of vasopressin by IRAP
is physiologically relevant (Nakada et al., 2011). In this study, an
increased 28-day mortality in sepsis, which was accompanied by
an increased vasopressin clearance,was associatedwith a SNP (sin-
gle nucleotide polymorphism: rs4869317) located in a regulatory
region of the IRAP gene that may alter the transcription of the
gene.
IRAP ACTION ON NEUROPEPTIDES INVOLVED IN LEARNING AND
MEMORY
Next tohormones andvasoactive peptides,neuropeptides involved
in learning and memory represent an important group of IRAP
substrates. Given that memory can be improved by angiotensin IV
(AT4) administration (Braszko et al., 1988), the surprising identiﬁ-
cation of IRAPas a high afﬁnityAT4 receptor in the brain (Albiston
et al., 2001) prompted many efforts aiming at characterizing the
role of IRAP role in memory and learning. The group of Albis-
ton and Chai showed ﬁrst that AT4 is a high-afﬁnity inhibitor
of IRAP by binding to the active site of the enzyme (Lew et al.,
2003) and developed later a new class of IRAP inhibitors which
are cognitive enhancers (Albiston et al., 2008). Several hypothetical
mechanisms were initially considered for memory enhancement
induced byAT4 (Stragier et al., 2008). However, it remains difﬁcult
today to draw a conclusion concerning the role of IRAP as an AT4
receptor and in memory mechanisms. Even the analysis of IRAP
deﬁcient mice did not shed much light on this issue. A clear result
obtained using these mice is that in the absence of IRAP the high
afﬁnity-binding site for AT4 is lost in the brain and other tissues,
providing strong evidence that IRAP is the AT4 receptor (Albis-
ton et al., 2010). This result is important, considering that the
AT4 receptor identity was controversial until recently (De Bundel
et al., 2008; Stragier et al., 2008; Wright et al., 2008). Neverthe-
less, the analysis of the memory phenotype of IRAP deﬁcient mice
displayed unexpected results. Despite the fact that acute admin-
istration of IRAP inhibitors increases memory, constitutive IRAP
deletion in mice does not improve memory (Albiston et al., 2010).
TISSUE DISTRIBUTION AND INTRACELLULAR LOCALIZATION
Even though IRAP was ﬁrst identiﬁed and thus extensively stud-
ied in adipocytes, the enzyme is expressed in a very large array of
tissues. Initially, IRAP was detected by immunoblot at similarly
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high levels in heart, spleen, brain, lung, and adipose tissues and at
low level in kidney and muscles. The only tissue in which IRAP
amounts were below the limit of immunoblot detection was the
liver (Keller et al., 1995). Subsequently a more detailed analysis
was performed on brain, placenta, and spleen cells, showing that
the enzyme has a cell-speciﬁc expression pattern. In the brain its
expression is restricted to hippocampus, neocortex, and motor
neurons (Fernando et al., 2005). In the placenta, IRAP is expressed
mainly in differentiated cells in the trophoblast and the syncy-
tiotrophoblast (Nomura et al., 2005). In the spleen the enzyme is
detected in dendritic cells (DCs), B cells, T cells (with highest level
of expression observed in conventional CD11chigh DCs), and it is
absent from granulocytes (Saveanu et al., 2009).
In all the studied cells the enzyme resides in endosomal vesicles.
IRAPvesicles recycle slowly in thebasal state and canbe rapidly and
massively translocated to the plasmamembrane upon cell-speciﬁc
stimulation. These vesicles are often called GSV or insulin respon-
sive compartment (IRC) in adipocytes and muscle cells. Since
there is no obvious difference between IRAP-containing endo-
somes in different cell types, we prefer to name the IRAP vesicles
“cell-speciﬁc storage endosomes.” It is now well established that
the entire information required for the endosomal localization of
IRAP, for its slow recycling and its sensitivity to cell-speciﬁc regula-
tion is encoded by the N-terminal cytosolic tail of the protein. For
example, a chimera between the N-terminal IRAP domain and the
transferrin receptor (TfR) displayed the same intracellular local-
ization and trafﬁcking as the full-length IRAP (Subtil et al., 2000;
Hou et al., 2006). Fusion proteins composed by the IRAP cytosolic
tail and TfR or EGFP were extensively used as tools to analyze the
consequences of different mutations in the targeting motifs that
are present in the cytosolic tail of IRAP. The most studied target-
ing sequences are the two dileucine motifs: LL53,54 and LL76,77.
The LL53,54 signal seems to be a form of the (D/E)XXXL(L/I)
type signal in which the acidic D or E residue is substituted with
a basic R residue (RXXXLL; Bonifacino and Traub, 2003). Inter-
estingly, GLUT4 also contains a RXXXLL sequence, and in this
context the RXXXLL signal seems to be important for routing of
endocytosed GLUT4 from the plasma membrane to the insulin
responsive storage vesicles (Sandoval et al., 2000). However, in the
case of IRAP, the substitution of LL53,54 byAA53,54 did not affect
the enzyme trafﬁcking in differentiated 3T3-L1 adipocytes (Hou
et al., 2006). Unlike this mutation, the substitution of LL76,77 by
AA76,77 had a strong impact on IRAP localization and trafﬁck-
ing and resulted in rapid transport of newly synthesized IRAP
to the plasma membrane, in a manner indistinguishable from
other proteins constitutively directed to the plasma membrane
such as vesicular stomatitis virus G coat protein (VSV-G), GLUT1
or syntaxin3 (Watson et al., 2008).
Transient expression of IRAP–GFP demonstrated that newly
synthetized IRAP accumulates in storage endosomes as early as 3 h
after transfection (Watson et al., 2004). The acquisition of insulin
sensitivity starts at 6 h post transfection and is fully accomplished
after 9 h. During the ﬁrst 3 h after enzyme synthesis, IRAP trafﬁck-
ing is brefeldinA sensitive,but once it enters the storage endosomes
its translocation to the plasma membrane becomes insensitive to
brefeldin A treatment (Watson et al., 2008). In adipocytes, the
sorting of newly synthesized IRAP from the trans-Golgi network
(TGN) to the storage endosomes requires the clathrin adaptor
GGA1, a member of the γ-ear-containing, ADP-ribosylation fac-
tor (Arf)-binding (GGA) family of clathrin adaptors (Figure 1;
Liu et al., 2005; Hou et al., 2006). A chimera between the cytosolic
IRAP tail bearing the AA76,77 mutation and the TfR bypasses the
GGA1 dependent sorting step in the TGN, but once it arrives at
the plasmamembrane it can be endocytosed normally, reaches the
storage endosomes and is even able to translocate back to the cell
surface upon insulin treatment (Watson et al., 2008).
REGULATION OF IRAP TRAFFICKING
SIGNALING PATHWAYS INVOLVED IN IRAP TRAFFICKING REGULATION
The regulation of IRAP trafﬁcking is understood by far in most
detail in insulin responsive tissues, mainly in adipocytes, where
it has been studied for nearly two decades. As already mentioned
before, in these cells, IRAP and GLUT4 are co-localizing in stor-
age endosomes called GSV. Insulin stimulates glucose uptake into
adipocytes by stimulating translocation of GLUT4 from the stor-
age endosomes to the plasma membrane (Antonescu et al., 2009).
In the absence of insulin, GLUT4 is stored by active mechanisms
and sequestered away from the common recycling endosomes
(Martin et al., 2006). GLUT4 exocytosis to the plasma membrane
from the storage endosomes is very slow compared with gen-
eral exocytosis from recycling endosomes (Zeigerer et al., 2004).
Insulin accelerates GLUT4 and IRAP transport to the cell sur-
face and simultaneously reduces GLUT4 internalization having as
a global effect a rapid increase of GLUT4 in the plasma mem-
brane of insulin-stimulated adipocytes. The insulin receptor is a
member of the tyrosine kinase receptor family. Binding of insulin
FIGURE 1 | IRAP storage vesicles are slow recycling endosomes. Newly
synthetized IRAP accumulates in storage endosomes as early as 3 h after
transfection (Watson et al., 2004) and acquires insulin responsiveness after
6–9 h. During the ﬁrst 3 h after enzyme synthesis, IRAP sorting from the ER
is brefeldin A sensitive. Once the enzyme reaches the storage endosomes
its translocation to the plasma membrane becomes insensitive to brefeldin
A treatment (Watson et al., 2008). Sorting of newly synthetized IRAP from
theTGN to the storage endosomes in adipocytes requires the GGA1
clathrin adaptor (Liu et al., 2005; Hou et al., 2006) and the LL76,77
sequence in the cytosolic domain of IRAP (Watson et al., 2008).
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to its receptor induces receptor autophosphorylation on several
cytoplasmic tyrosines and the rapid recruitment and phospho-
rylation of the effector proteins insulin receptor substrate 1 and
2 (IRS1, IRS2), and Shc (Goalstone and Draznin, 1997). Tyro-
sine phosphorylation of IRSs induces the binding of SH2 domains
of the regulatory subunits of class I-A PI3Ks, which initiate the
subsequent intracellular signaling. Brieﬂy, the PI3K activity pro-
duces the lipid PtdIns(3,4,5)P3, which will recruit to membranes
the phosphoinositide-dependent kinase-1 (PDK1) and PDK1 sub-
strates, including the kinases of Akt/PKB family (Siddle, 2011).
There are three Akt proteins: Akt1, Akt2, and Akt3, which are
encoded by separate genes and which have different functional
speciﬁcities.
Production of different Akt deﬁcient mice demonstrated that
Akt1 is important for cell survival, while Akt2 deﬁcient mice have
impaired glucose homeostasis and develop type II diabetes and
Akt3 deﬁciency induces abnormal brain development (Gonza-
lez and McGraw, 2009a). Even though both Akt1 and Akt2 can
be recruited to the plasma membrane after PI3K activation, it
has been shown by TIRF microscopy that it is mainly Akt2 that
is recruited to the plasma membrane upon insulin stimulation.
Moreover, siRNA knockdown of Akt2 demonstrated that the pro-
tein is required for GLUT4 translocation in response to insulin
stimulation (Gonzalez and McGraw, 2009b). These in vitro data
correlated with the phenotype of Akt2 deﬁcient mice and sug-
gest that Akt2 is the essential Akt isoform controlling trafﬁcking
of IRAP–GLUT4 storage endosomes in adipocytes. Nevertheless,
a functional overlap among the three Akt isoforms exists. This is
suggested by the fact that mice with a single Akt isoform dele-
tion are viable, while mice with double knockouts for Akt are
not. The simultaneous deletion of Akt1 and Akt2 leads to death
immediately after birth (Peng et al., 2003) and Akt1 and Akt3
double knockout mice are embryonic lethal (Yang et al., 2005).
The overlapping roles of Akt1 and Akt2 could also be involved
in particular situations in IRAP–GLUT4 trafﬁcking in adipocytes.
For example, forced localization of Akt1 to the plasma membrane
[via E17K mutation of Akt1 (Gonzalez and McGraw, 2009b) or
by addition of a myristoyl group to Akt1 (Kohn et al., 1996)] was
demonstrated to induce an Akt2-like signaling and translocation
of GLUT4 vesicles (and probably IRAP) to the plasma membrane.
PROTEIN INTERACTIONS OF THE CYTOSOLIC DOMAIN OF IRAP
In adipocytes andmuscles PI3K-PDK1-Akt are the protein kinases
that are activated in a cascade after insulin receptor stimulation
and Rab8, Rab10, and Rab14 the small GTPases that drive GSV
translocation to the cell surface. Much of the work leading to
the description of this signaling pathway (Figure 2) was carried
out using GLUT4 or IRAP as markers of GSV, without discrim-
inating between the function of these proteins as simple cargo
or active players in GSV trafﬁcking. It is important to note that
several ﬁndings suggest that both proteins, and especially IRAP,
might have more complex roles than simple cargos in vesicular
trafﬁcking. First, it was observed that deletion of either of these
proteins affects the stability of the other. Mice deﬁcient for IRAP
(Keller et al., 2002) displayed a reduced level of GLUT4 protein
(50–80% reduction) and mice deﬁcient for GLUT4 had a redistri-
bution of IRAP to the plasmamembrane (Jiang et al., 2001). These
in vivo data, which reﬂect the situation in primary adipocytes
isolated frommice,were only partially conﬁrmed by in vitro exper-
iments using siRNA knockdown of GLUT4 and IRAP in 3T3-L1
adipocytes (Jordens et al., 2010). In 3T3-L1 adipocytes, GLUT4
knockdown does not change the distribution of IRAP between the
plasma membrane and intracellular vesicles, indicating that IRAP
trafﬁc is independent of GLUT4. However, the IRAP knockdown
in 3T3-L1 differentiated adipocytes affected GLUT4 trafﬁcking,
increasing three times its level at the plasma membrane. At the
same time, intracellular GLUT4 was partially rerouted to consti-
tutive endosomes that contain the TfR. When insulin was added
to IRAP knockdown adipocytes, the level of GLUT4 at the plasma
membrane increased further to a similar extent as inwt adipocytes.
Thus, IRAP is required for intracellular retention of GLUT4 but
not for sensitivity of its localization to insulin stimulation. The
expression of the cytosolic tail of IRAP was sufﬁcient to recover
the normal intracellular distribution of GLUT4 in IRAP knock-
down adipocytes. The concomitant analysis of the TfR in IRAP
knockdown adipocytes showed that its trafﬁcking was not affected
FIGURE 2 | Cell-specific regulation of IRAP storage vesicles. (A) In
insulin-responsive tissues, such as adipocytes and muscles, IRAP trafﬁcking is
regulated by insulin. Upon insulin binding to its receptor, PI3K-PDK1-Akt
protein kinases are activated in a cascade. The most important effector in
these cells seems to be the RabGAP AS160, which is phosphorylated by
Akt2. Phosphorylation of AS160 leads to its dissociation from the storage
endosomes and activation of Rab8, Rab10, and Rab14 that drive the
endosome translocation to the cell surface. The biological effect is the
increase at cell surface of the principal vesicle cargo, the glucose transporter
GLUT4. (B) In other cells, the stimuli that regulate IRAP endosome trafﬁcking
and the signaling pathways involved in this process are poorly characterized.
In DCs, IRAP endosomes are recruited rapidly to the phagosomal membrane.
The phagocytic receptors and the signaling molecules responsible for this
phenomenon are not yet identiﬁed.
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by the absence of IRAP, indicating that the role of IRAP is speciﬁc
to the trafﬁcking of storage endosomes and does not regulate con-
stitutive TfR+ recycling endosomes (Jordens et al., 2010). Thus
recruitment of the sortingmachinery for GLUT4 targeting to stor-
age endosomes is at least partially accomplished by the cytosolic
domain of IRAP. The cytosolic domain of IRAPmight recruit sort-
ing machinery components since it interacts with several proteins
implicated in protein sorting, vesicle formation, and coupling of
the signaling pathways with cytoskeleton remodeling.
Early after its identiﬁcation, IRAP was found to interact with
tankyrase-1 and 2 (Chi and Lodish, 2000), two modular pro-
teins with both poly(ADP)-ribosylation enzymatic activity and
scaffolding activities. Tankyrases interact via their ankyrin-repeat
domain with diverse partners having multiple biological roles.
Among the complex functions attributed to tankyrases, the impli-
cation in regulation of Golgi vesicle trafﬁcking and the regulation
of protein targeting in response to growth factor signaling are
especially relevant in the context of their interaction with IRAP.
The identiﬁcation of the “RXXPDG” sequence as the tankyrase-
bindingmotif of IRAP (Sbodio andChi, 2002)might allow a better
comprehension of the IRAP-tankyrase interaction viamutagenesis
experiments.
Another protein involved in the transport between Golgi stacks
that was found to interact directly with the cytosolic tail of IRAP
is p115 (Hosaka et al., 2005), which assists vesicle fusion by assem-
bling SNARE pin complexes. In addition to these Golgi proteins
interacting with IRAP, co-immunoprecipitation experiments and
yeast two-hybrid analysis revealed the interaction of the cytosolic
domain of IRAP with two cytoskeleton-linked factors: vimentin
(Hirata et al., 2011) and FHOS (formin homolog overexpressed in
the spleen; Tojo et al., 2003). Vimentin is a part of intermediate
ﬁlaments in the cytoskeleton, which support and anchor cellular
organelles. Formins are multidomain proteins essential for actin
polymerization that are involved in the transport of vesicles on
actin cables (Goode and Eck, 2007). Since the cytosolic part of
IRAP interacts with a protein important in organelle anchoring
to the cytoskeleton and another protein involved in guided endo-
some motility along the cytoskeleton, it is tempting to speculate
that the IRAP cytosolic tail regulates GSV trafﬁcking and possibly
specialized sorting in several other cell types. It will be of interest to
conﬁrm these protein interactions of IRAP in different cell types
and assess their function in the regulation of storage endosome
trafﬁcking.
Additional indications about a regulatory role of IRAP in
GSV trafﬁcking came from two recent studies that reported
an interaction between the cytoplasmic domain of IRAP and a
well-characterized Akt substrate, the RabGAP AS160, an interac-
tion detected by reciprocal co-immunoprecipitation experiments
(Larance et al., 2005; Peck et al., 2006). The IRAP sequence
required for the interaction with AS160 was mapped to the region
between amino acids 27 and 58 of the IRAP cytosolic domain
(Larance et al., 2005). Because the presence of AS160 on GSV is a
key player in intracellular retention of GSV in the basal state, the
interaction of AS160with IRAP supports the hypothesis that IRAP
is a critical component of GSV retention machinery. However,
another recent study concluded that IRAP knockdown in 3T3-
L1 adipocytes affect neither AS160 association with GSV nor its
regulation by insulin via PI3K-Akt-AS160 (Jordens et al., 2010).
It seems therefore that IRAP is not essential for the targeting of
AS160 to GSV and even if IRAP binds AS160, additional sites of
interaction for AS160 with GSV membranes must exist.
IRAP TRAFFICKING IN IMMUNE CELLS
Among the cell types of the immune system, IRAP was only stud-
ied in mast cells (Liao et al., 2006) and DCs (Saveanu et al.,
2009; Segura et al., 2009). In bone marrow-derived mast cells and
in rat peritoneal mast cells, IRAP is highly expressed and local-
izes to intracellular vesicles. IRAP vesicles in mastocytes contain
VAMP3 and VAMP2 and are different from the secretory granules
since there is no overlap between IRAP and histamine or CD63,
which are markers of secretory granules. By cell-surface biotinyla-
tion experiments, Liao et al. demonstrated that IRAP translocates
rapidly to the plasma membrane upon stimulation of mast cells
by antigen/immunoglobulin E (IgE) complexes. While exocytosis
of mast cell secretory granules following stimulation by antigen-
IgE complexes requires PI3K and PKC activities, export of IRAP
endosomes to the cell surface is independent of PKC and PI3K
activities but depends on intracellular calcium. Thus, interestingly,
in mast cells the same extracellular signal, antigen-IgE complexes,
induce exocytosis of two intracellular vesicle pools, secretory gran-
ules and IRAP vesicles, although the signaling pathways regulating
these transport events are different. Contrary to what would be
expected by analogy with adipocytes, the activation of PI3K does
not induce IRAP translocation to the plasma membrane. These
results highlight the cell-speciﬁc behavior of IRAP endosomes and
show that results obtained in a given cell type cannot readily be
extended to others.
We analyzed the intracellular distribution of IRAP in sev-
eral types of DCs: human monocytes-derived DC, murine bone
marrow-derived DC (BMDCs; Saveanu et al., 2009), splenic DC
subsets (conventional CD8+ and CD8− DCs and plasmacytoid
DCs, pDCs; Weimershaus et al., 2012). In all DC subsets ana-
lyzed, the enzyme colocalized at high levels (more than 50% of the
total IRAP signal) with Rab14, syntaxin 6 (STX6), and the type1-
mannose receptor (MR, alternatively named CD206) and to lesser
extent (20 to 30% of total IRAP signal) with EEA1 andMHC class
I. The extracellular stimuli and the signaling pathways that regulate
IRAP endosomes trafﬁcking in DCs are yet unknown. By several
experimental approaches (immunoﬂuorescence microscopy, cell
fractionation, ﬂow cytometry analysis of isolated phagosomes),
we have demonstrated that IRAP endosomes are recruited to early
phagosomes in DCs (Saveanu et al., 2009; Weimershaus et al.,
2012),but the phagocytic receptors that induce IRAP vesicle fusion
with the phagosome are still unknown.
IMMUNOLOGICAL FUNCTION OF THE ENZYME
Our initial observation that connected IRAP with MHC class I
antigen presentation was the co-puriﬁcation of these two pro-
teins during the screening of crude human microsome lysates
for enzymes involved in aminoterminal trimming of MHC
class I ligands. IRAP and MHC class I were identiﬁed from
an IFN-γ-induced peak of aminopeptidase activity isolated by
anion exchange chromatography. Surprisingly, subsequent analy-
ses showed that while MHC class I protein synthesis was strongly
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increased, IRAP mRNA was not up-regulated upon IFN-γ treat-
ment of HeLa cells. This suggested that either IRAP changed its
intracellular localization upon IFN-γ treatment or that increased
recovery of IRAP activity was the consequence of its association
with IFN-γ-induced MHC class I. While the former hypothesis
remains tobe studied indetail, associationof IRAPwithMHCclass
I molecules was conﬁrmed by reciprocal co-immunoprecipitation
experiments in murine BMDCs (Saveanu et al., 2009), as well as
in human lymphoblastoid cell lines (our unpublished data).
TRIMMING OF ANTIGENIC PEPTIDES BY IRAP
The ability of IRAP to digest peptide precursors of MHC class I
ligands was demonstrated by several teams. Initially we demon-
strated that IRAP puriﬁed from human microsomes, as well as
the recombinant enzyme, efﬁciently processed two MHC class I
ligand precursors: the HIV gag derived peptide, R-SLYNTVATL
and the HIV gp160 derived peptide, KIRIQR-GPGRAFVTI (ﬁnal
epitope underlined; Saveanu et al., 2009). Equivalent amounts
of isolated ERAP1 or ERAP2 were relatively inefﬁcient in the
production of the ﬁnal epitope from the HIV gp160 precursor,
which needs the combined action of ERAP1–ERAP2 (Saveanu
et al., 2005b). Notably, IRAP was as efﬁcient as the ERAP1–ERAP2
mixture in the generation of HIV gp160 ﬁnal epitope, suggest-
ing that the speciﬁcity of IRAP resembles that of ERAP1 and
ERAP2 combined. The group of Stratikos conﬁrmed this ﬁnding
in two subsequent reports that analyzed the substrate speciﬁcity
of ERAP1, ERAP2, and IRAP (Georgiadou et al., 2010; Zervoudi
et al., 2011). Using ﬂuorogenic analogs of peptide substrates, they
demonstrated that IRAP has broader substrate speciﬁcity than
isolated ERAP1 or ERAP2 and a broader pH range for optimal
activity. However, as it has been demonstrated for ERAP1 (Hearn
et al., 2009), the aminopeptidase activity against ﬂuorogenic sub-
strate does not always match the speciﬁcity of trimming natural
peptides. Therefore, testing IRAP speciﬁcity against peptide sub-
strates with systematic variation of the N-terminal residues needs
further experimental work. The relative pH independence of IRAP
makes the enzyme more appropriate for antigen trimming in
endosomes, known for their dynamic pH changes. Taking advan-
tage of the availability of the crystal structure of ERAP1 (Kochan
et al., 2011; Nguyen et al., 2011) and the high similarity between
these trimming aminopeptidases, the structure of ERAP1was used
to make homology models of the other two aminopeptidases,
which allowed the analysis of S1 pocket of all enzymes (Zervoudi
et al., 2011). The S1 pocket is deﬁned by 12 amino acids. Six of
them are identical for all three enzyme and the other six confer the
substrate speciﬁcity. In direct correlation with the enzyme ability
to cleave basic amino acids, the S1 pocket has different numbers
of acidic amino acids: three for ERAP2 (E177, D198, and D888),
two for IRAP (E426 and E541), and only one for ERAP1 (E865).
Mutagenesis of E541 to R in the S1 pocket of IRAP resulted in a
selectivity proﬁle similar to that of ERAP1. The authors concluded
that residue E541 is largely responsible for the ability of IRAP to
process peptides that are substrates for ERAP2 in the ER.
Among trimming aminopeptidases, only human ERAP1 has
been studied extensively with respect to substrate speciﬁcity
(Chang et al., 2005; Hearn et al., 2009). Using peptide libraries
Chang et al. (2005) have demonstrated that human ERAP1 digests
optimally peptide with a length of 9–16 amino acids. The trans-
porter associated with antigen presentation (TAP) has an identi-
cal length preference for the substrate (van Endert et al., 1994).
Given the concordance between ERAP1 and TAP substrate length
speciﬁcity, Chang et al. proposed the attractive model of “mole-
cular ruler” action for ERAP1. According to this model, ERAP1
is exceptionally adapted to produce MHC class I peptides that
have typically 8–10 amino acids length. There are arguments for,
and against, the molecular ruler model of ERAP1 mode of action.
Several studies in vitro showed that ERAP1, as well as its murine
homologERAAP,could destroy several epitopes,ﬁndings in poten-
tial conﬂict with the molecular ruler model (Serwold et al., 2002;
York et al., 2002; Georgiadou et al., 2010). On the other hand, the
structural analysis of ERAP1 offered amechanism for the molecu-
lar ruler model. According to Nguyen et al. (2011), the enzyme has
a regulatory site close to the catalytic site and only long peptides
are capable to bind to the regulatory site, inducing the conforma-
tional change required for catalytic activity. Next to the structural
analysis, one of the strongest arguments for the molecular ruler
mode of action of ERAP1 is perhaps the fact that not only the
amino terminal residues, but also the carboxy-terminal residues
of the peptide substrate control the trimming efﬁciency, indicat-
ing that the enzyme interacts with both peptide ends at the same
time (Chang et al., 2005).
The lack of both a systematic analysis of its trimming activity
and of a crystal structure does not allow for predicting if IRAP has
substrate length or sequence preferences. Georgiadou et al. (2010)
performed the so far most detailed analysis of antigenic peptide
trimming activity of IRAP. They evaluated the trimming of 14 pep-
tide precursors by IRAP and ERAP1. ERAP1 produced the ﬁnal
epitopes in 13 out of 14 and IRAP in 10 out of 14 cases. The authors
concluded that, like ERAP1, IRAP can trim long antigenic peptides
efﬁciently and, in the majority of cases, it accumulates consider-
able amounts of ﬁnal antigenic epitope. It is important tomention
that both peptidases destroyed some of the ﬁnal epitopes analyzed.
ERAP1 over-digested 6 and IRAP 9 of the 14 precursors. The num-
ber of peptides processed in this study is too small to evaluate the
substrate length speciﬁcity of IRAP.However,a look at the analyzed
peptide sequences suggests that IRAP has preferences unrelated to
the N-terminal residue, since the same residues are removed with
different efﬁciency depending on the studied peptide. In conclu-
sion, the enzymatic activity data available today indicate that IRAP
is capable to trim MHC class I peptide precursors.
THE ROLE OF IRAP IN MHC CLASS I ANTIGEN PROCESSING
Analysis of BMDCs from IRAP deﬁcient mice allowed us to
demonstrate that IRAP trimming activity is not required for direct
presentation (or endogenous presentation) by MHC class I of
two model epitopes: the SIINFEKL peptide, an H-2Kb restricted
epitope derived from ovalbumin and the KCSRNRQYL peptide,
a Db restricted epitope derived from the SMCY male antigen
(Saveanu et al., 2009). The production of these two epitopes in the
endogenous processing pathway requires ERAP and proteasome
activity, but not IRAP. These results strongly suggested that IRAP
is not involved in the endogenous MHC class I processing path-
way and are in concordance with the endosomal localization of
IRAP. In steady-state conditions, in humanmonocyte-derivedDCs
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(moDCs) and murine BMDCs, we could not detect colocalization
of IRAPwith ER-resident proteins such as ERAP1,TAP, calnexin or
theKDEL receptor.Using ER-targeted variants of IRAP,we veriﬁed
that the absence of IRAP colocalization with ER markers was not
due to the inability of antibodies to recognize ER-resident IRAP.
When the KDEL sequence was added to the C-terminal end of the
enzyme, the IRAP-speciﬁc antibodies detected a strong colocaliza-
tion of IRAP with two ER markers: TAP and the KDEL receptor.
We concluded that the endogenous newly synthesized IRAPmole-
cules exit rapidly from the ER and travel to endosomes containing
Rab14, STX6, and MR.
The endosomes containing IRAP are massively recruited to
early phagosomes (Saveanu et al., 2009). This was demonstrated
by ﬂuorescence microscopy experiments and immunoblot analy-
sis of isolated phagosomes containing latex beads. In the same
experimental settings we could not detect the murine ER pepti-
dase (ERAP1/ERAAP) in the phagosomes. These results were in
agreement with the proteomic analysis of latex beads phagosomes
carried out by Rogers and Foster (2007) who detected IRAP, but
not ERAP, in isolated phagosomes. Thus, in our hands, IRAP was
the sole member of the oxytocinase family of potential trimming
aminopeptidases present inDCphagosomes.The absenceof ERAP
in phagosomes is of particular interest considering the previous
reports suggesting a fusion between ER membranes and newly
formed phagosomes (Ackerman et al., 2003; Guermonprez et al.,
2003; Houde et al., 2003) and the later controversy concerning the
existence and relevance of this phenomenon (Touret et al., 2005).
Our results suggest that the ER-phagosome fusion is a selective
process, which can provide integral membrane proteins as TAP to
the phagosome, but not soluble proteins such as ERAP.
The endosomal andphagosomal localization of IRAP suggested
that IRAP might be involved in MHC class I cross-presentation
of exogenous antigens. Indeed, IRAP deﬁciency partially com-
promised cross-presentation of ovalbumin antigen internal-
ized through phagocytosis both in vitro (cross-presentation of
ovalbumin-coated latex beads and necrotic cells expressing oval-
bumin by BMDCs) and in vivo (mice immunizedwith ovalbumin-
polyI:C loaded apoptotic cells). Moreover, IRAP was required for
efﬁcient in vivo cross-presentation of ovalbumin internalized by
receptor-mediated endocytosis (Saveanu et al., 2009; ovalbumin
fusion proteins targeted to TLR2 and MR; Kratzer et al., 2010).
Importantly, IRAP was involved in a cross-presentation path-
way that also requires proteasome activity. While IRAP deﬁciency
decreased the ability of DCs to cross-present ovalbumin by about
half, proteasome inhibition (using conditions strictly controlled
to avoid toxic side effects) almost abolished cross-presentation
completely. These experiments suggested that the initial steps in
processing of cross-presented epitopes are almost exclusively per-
formed by the proteasome, while more than one enzyme can
perform the last step of antigen processing, the aminoterminal
trimming. Analysis of ERAP-deﬁcient mice and BMDCs had pre-
viously identiﬁed ERAP as another enzyme that can perform
the aminoterminal trimming of cross-presented peptides (Yan
et al., 2006; Firat et al., 2007). Consistent with this, we found
that the absence of either IRAP or ERAP alone reduced cross-
presentation of ovalbumin by about half, while the simultaneous
deletion of ERAP and IRAP had an additive effect (Saveanu
et al., 2009). This functional redundancy, correlated with the
absence of ERAP–IRAP colocalization, led us to the hypothe-
sis that the two enzymes act in two independent pathways of
proteasome-dependent cross-presentation.
AN UPDATED VIEW OF CROSS-PRESENTATION PATHWAYS
Classically, cross-presentation is divided in two pathways: one that
is TAP and proteasome-dependent and one that is TAP and pro-
teasome independent. In the proteasome independent pathway,
commonly referred to as vacuolar cross-presentation, internal-
ized exogenous antigens remain in endocytic vesicles where they
are processed by acidic lysosomal proteases, with a prominent
role for the cathepsin S (Shen et al., 2004) and where loading of
the MHC class I molecules occurs. In the proteasome-dependent
pathway, which is considered more efﬁcient than the vacuolar
pathway (Sigal and Rock, 2000), the antigens are shuttled into
the cytosol. Several groups demonstrated that intact, functional
proteins such as the toxin gelonin, the enzyme horseradish per-
oxidase (HRP), or ovalbumin internalized by macrophages and
DCs are transferred to the cytosol where they are digested by
the proteasome (Kovacsovics-Bankowski and Rock, 1995; Nor-
bury et al., 1995; Rodriguez et al., 1999). One possibility is that the
resulting peptides are transported by TAP into the perinuclear
ER where they bind to newly synthesized MHC class I mole-
cules (Gromme and Neefjes, 2002; Rock and Shen, 2005). In the
context of the latter model, ERAP involvement in proteasome-
dependent cross-presentation is an expected ﬁnding. However,
both experimental observations suggesting fusion between the ER
and phagosomes and our discovery that endosomal IRAP plays a
role in cross-presentation suggest strongly that MHC class I load-
ing with cross-presented peptides is not limited to the perinuclear
ER and can occur in endosomal or phagosomal compartments.
Independent of our work, several recent reports have put
forward endosomal subpopulations as active players in cross-
presentation (Burgdorf et al., 2007, 2008; Kutomi et al., 2009).
It has been demonstrated that ovalbumin endocytosed via the
MR reaches an early endosomal compartment (EEA1+, Rab5+)
distinct from lysosomes, which enables cross-presentation, while
ovalbumin ingested via pinocytosis reaches lysosomes and results
in antigen presentation via MHC class II (Burgdorf et al., 2007).
Burgdorf proposed that MR+ endosomes are likely to be iden-
tical or largely overlap with the early static endosomes described
earlier (Lakadamyali et al., 2006). By tracking ﬂuorescent Rabs
in live cells, these authors demonstrated that early endosomes
consist of two distinct populations: one highly mobile on micro-
tubules and maturing rapidly toward lysosomes and a second
“static”maturing much more slowly. Since it is now clearly estab-
lished that the efﬁciency of antigen cross-presentation is enhanced
by limiting proteolysis and maintaining a close to neutral pH in
endolysosomes (Savina et al., 2006; Jancic et al., 2007), it would
be interesting to test the overlap of mannose receptor with “static”
slowly maturating early endosomes. The substantial colocaliza-
tion of IRAP with the MR (50–75% depending on the DC type
analyzed) and the colocalization of the enzyme with EEA1 and
endocytosed soluble ovalbumin (Saveanu et al., 2009; Weimer-
shaus et al., 2012) designate IRAP as an optimal candidate for
antigen trimming in these endosomes.
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Wehave found that IRAPwas strongly recruited to early phago-
somes, where it colocalized with internalized MHC class I and
phagocytized antigen. At later time points, when the phagosome
was converted to a phagolysosome, the enzyme and MHC class I
molecules were detected only in isolated endosomes, often adja-
cent to the phagosome, but not within. Therefore, IRAP storage
endosomes seem to accumulate internalized MHC class I mol-
ecules. However, we have not explored whether IRAP vesicles
can pinch out internalized antigen and MHC class I during the
membrane fusion and ﬁssion events occurring during phagosomal
maturation.
Our data suggest strongly that MHC class I loading with
cross-presented peptides takes place in endocytic vesicles, but
it is impossible to ascertain whether these vesicles are endo-
somes or phagosomes. One argument for loading events in the
phagosome derives from the phenomenon of ER-phagosome
membrane fusion (Ackerman et al., 2003; Guermonprez et al.,
2003; Houde et al., 2003). Several groups demonstrated originally
that ER-resident proteins, including key factors of the antigen-
presenting machinery (TAP, Tapasin, Calnexin) and Sec61 are
associated with the phagosome. Based on these results, it was
proposed that the phagosome becomes an autonomous cross-
presentation compartment according to the following scenario:
phagocytized antigen is transported to cytosol via Sec61,processed
by the proteasome and the peptides generated in the cytosol
are re-imported by phagosomal TAP complexes and loaded on
class I molecules within the phagosome. However, this model
was challenged later, when Touret et al. (2005) did not detect
any signiﬁcant contribution of the ER to forming or matur-
ing phagosomes in macrophages or DCs. Although the rea-
sons for this discrepancy remain unclear, different experimental
conditions may be the explanation: use of opsonized vs non-
opsonized antigen, or possible interference from contaminating
TLR ligands that could change phagosomal maturation andmem-
brane fusion events. Molecular characterization of the fusion
mechanism and of the proteins controlling the fusion event
likely will eventually help to settle this controversy and evalu-
ate the relative contribution of ER-phagosome fusion to overall
cross-presentation.
In the light of the experimental data available today, we pro-
pose that proteasome-dependent cross-presentation can use at
least three intracellular compartments for MHC class I loading
with cross-presented peptides (Figure 3): the perinuclear ER,
phagosomes, and specialized endosomes. MHC class I loading
in compartments distinct from the ER in proteasome-dependent
cross-presentation is supported also by our recent analysis of
TAP deﬁcient BMDCs (Merzougui et al., 2011). We have found
that restoration of cell-surface MHC class I molecules on TAP
deﬁcient BMDCs by low temperature (26˚C) pre-incubation
normalizes cross-presentation of phagocytized ovalbumin, but
not cross-presentation of receptor targeted soluble ovalbumin.
Surprisingly, restored cross-presentation by TAP deﬁcient cells
requires antigen degradation by the proteasome. These ﬁndings
suggest that the principal role of TAP in proteasome-dependent
cross-presentation may be to ensure to provide sufﬁcient lev-
els of cell-surface class I molecules that can be loaded dur-
ing recycling through phagosomal compartments. Our results
also indicate that a TAP-independent mechanism for import
of antigenic peptides from the cytosol into phagosomes might
exist.
CROSS-PRESENTATION PATHWAYS AND DC SUBSETS
According to our experimental ﬁndings, several proteasome-
dependent cross-presentation pathways identiﬁed by the nature
of the trimming peptidase involved can operate simultaneously in
DCs (Figure 3): (i) a cytosol to ER pathway where the trimming
aminopeptidase is ERAP and (ii) a cytosol to endosome pathway
dependent on IRAP. For antigens that are shuttled in the cytosol the
possibility of cytosolic trimming of peptide precursors also exists.
Cytosolic trimming, considered to have a minor impact on overall
MHC-I presentation (vanEndert, 2011), could be essential for spe-
ciﬁc epitopes, as for example an epitope derived from the EBNA3C
protein of Ebstein Barr virus, which requires nardilysin for amino
terminal trimming (Kessler et al., 2011). The relative importance
of these pathways in antigen processing may depend on a variety
of factors including the nature of the antigen but also the DC sub-
set involved. DCs are a heterogeneous cell population (Shortman
and Naik, 2007). Leaving aside tissue resident DCs and migra-
tory DCs, the spleen and the lymph nodes contain at least three
main DC subsets in steady-state conditions: pDCs, CD8+, and
CD8− conventional DCs (cDCs). Equivalents of these splenic DC
subsets can be obtained in vitro by FMS-like tyrosine kinase 3 lig-
and (Flt3L) differentiated cultures of murine BMprecursors (Naik
et al., 2005). In inﬂammatory conditions, a new population of
DCs, called moDCs arise from blood monocytes. The equivalents
of moDCs are obtained in vitro by culturing murine BM precur-
sors or human blood monocytes in the presence of granulocyte
macrophage colony stimulating factor (GM-CSF) and Interleukin
4 (IL-4; Inaba et al., 1992). pDCs are best known for their ability
to secrete high amounts of type I interferons (Reizis et al., 2011),
CD8+ DCs for their competence in antigen cross-presentation
(Hildner et al., 2008; Lin et al., 2008) and CD8− DCs for their
ability to present antigens via MHC class II (Dudziak et al., 2007).
moDCs, which proliferate strongly upon inﬂammatory stimuli,
are responsible in vivo for highly efﬁcient cross-presentation of
gram-negative bacteria and soluble antigens in the presence of
TLR ligands (Cheong et al., 2010).
A given DC subset could use preferentially the “cytosol to
the ER” or the “cytosol to endosome” pathway of proteasome-
dependent cross-presentation. An initial report by Segura et al.
(2009) suggested that the cross-presentation pathway involving
IRAP and MR is functional only in moDCs. The same authors
found that all steady-state DCs have similar amounts of IRAP but
did not observe IRAP colocalization with internalized ovalbumin
in cell fractionation experiments.We have recently analyzed pDCs
and CD8+ and CD8− cDCs (ex vivo sorted from the spleens as
well as their equivalents obtained fromFlt3L cultures) with respect
to expression and intracellular localization of IRAP and to the abil-
ity to cross-present soluble ovalbumin and yeast cells displaying
ovalbumin at cell surface.
Our recent results (Weimershaus et al., 2012) lead to quite
different conclusions and indicate that cDCs employ IRAP in
cross-presentation. Like Segura and colleagues, we found iden-
tical IRAP protein levels in all DC subsets analyzed. Additionally,
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FIGURE 3 | Cross-presentation pathways. According to the involvement
of the proteasome in antigen processing cross-presentation is divided in
two main pathways: proteasome-dependent cross-presentation (left panel)
and vacuolar cross-presentation (right panel). The vacuolar
cross-presentation does not require proteasome activity; the entire antigen
processing and MHC class I loading with cross-presented peptides occur
inside the vacuole.The proteasome-dependent cross-presentation involves
the transport of the exogenous antigens (possibly by Sec61) into the DC
cytosol of the DC and generation of N-terminal extended precursors of
MHC-I ligands in the cytosol. The aminoterminal trimming of these peptide
precursors can occur in two different compartments: (i) in a cytosol to ER
pathway, epitope precursors will join the endogenous processing pathway
after their transport by TAP into the ER (Kovacsovics-Bankowski and Rock,
1995). In this case peptide trimming is carried out by ERAPs; (ii) in a
cytosol to endosome pathway, the precursors of class I ligands are
retro-transported into specialized endosomes (Burgdorf et al., 2008;
Saveanu et al., 2009) or into phagosomes (Guermonprez et al., 2003) and
ﬁnal trimming is performed by IRAP (Saveanu et al., 2009).
we looked at the intracellular distribution of IRAP in DC subsets.
In steady-state conditions, the enzyme colocalized with previously
known markers of storage endosomes: Rab14 and STX6. How-
ever, there was a slight but signiﬁcant increase in Rab14/IRAP
colocalization in CD8+ DCs in comparison with CD8− DCs in
steady-state. Considering that Rab14 is one of the small GTPases
that drives IRAP translocation upon cell activation, the increased
IRAP–Rab14 colocalization in CD8+ DCs may be the reason for
higher and prolonged recruitment of IRAP in the phagosomal
membrane of these cells. It is conceivable that fusion between
Rab14–IRAP endosomes and phagosome contributes to a delay in
phagosomal maturation since Rab14 recruitment to the phago-
somes prevents phagosome fusion with lysosomes (Kyei et al.,
2006; Kuijl et al., 2007). Different from the data obtained by
Segura et al. (2009) we also readily detected colocalization of
internalized ovalbumin with IRAP using cell fractionation and
ﬂuorescence microscopy. Moreover, in vitro cross-presentation of
soluble ovalbumin and yeasts displaying ovalbumin on the surface
was impaired in both CD8+ and CD8− cDCs in the absence of
IRAP (Weimershaus et al., 2012).
At ﬁrst glance, our results on IRAP role in DC subsets are con-
tradictory with those reported by Segura et al. (2009) Examination
of the experimental settings, such as for example, the timing of
antigen processing, the antigen dose, and themethod of DCprepa-
ration, can explain some of the observed differences. Multiple
cross-presentation pathways can produce the SIINFEKL peptide
from internalizedovalbumin.At least four proteolytic enzymes can
produce the SIINFEKL epitope from its precursors: cathepsin S in
endosomes (Shen et al., 2004), the trimming peptidases ERAP, and
IRAP (Serwold et al., 2002; Saveanu et al., 2009) and even cytosolic
proteasome complexes (Cascio et al., 2001). It is not surprising in
this situation that extended antigen-processing times or high anti-
gen doses overcome the cross-presentation defects observed in the
absence of IRAP, ERAP, or even TAP (Weimershaus et al., 2012).
There are several lines of evidence that the cell biology of CD8+
DCs is optimized for cross-presentation. For example, CD8+DCs
have the most efﬁcient transport of internalized antigens to the
cytosol (Lin et al., 2008), the closest to neutral phagosomal pH
(Savina et al., 2009) and an up-regulated MHC class I loading
machinery in comparison with the CD8− cDCs (Dudziak et al.,
2007). The maturation state of CD8+ DCs allowing these cells
to excel in cross-presentation assays was carefully examined very
recently. Using Flt3L BMDCs, Sathe et al. (2011) demonstrated
that newly formed CD8+ DC acquire their cross-presentation
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capacity in amaturation step (accompanied by CD103 cell-surface
expression) triggered by inﬂammatory cytokines such as GM-CSF,
IL3, or TLR ligands (CpG). Interestingly, CD8+ DCs from Flt3L
cultures treated with TGF-β up-regulated cell-surface CD103, but
did not cross-present. This indicated that CD103 is amarker of the
maturation stage but does not correlate with cross-presentation
capacity. The work of Sathe et al. highlighted that antigen cross-
presentation is not an innate feature of the CD8+ DC lineage,
but acquired after cell stimulation by cytokines and TLR ligands.
Dresch et al. conﬁrmed the fact that splenic CD8+ DCs require
stimulation by GM-CSF or CD40 ligand for acquisition of antigen
cross-presentation ability. In contrast, cross-presentation of solu-
ble and cell-associated ovalbumin by thymic CD8+ DCs is very
efﬁcient in the absence of licensing factors, such as GM-CSF or
CD40 ligand (Dresch et al., 2011).
Thus, peripheral CD8+ DCs, but not their thymic equivalents,
need maturation by CD40 ligand, GM-CSF or TLR stimulation
to activate the cross-presentation machinery. This recent conclu-
sion perfectly agrees with the longstanding concept that immature
DCs are poor antigen-presenting cells and that their activation is
crucial for the initiation of immunity (Banchereau and Steinman,
1998). It remains to be seen whether the numerous factors that
induce DC activation have an inﬂuence on the balance between
the cross-presentation pathways depicted in the Figure 3.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
Current data indicate that the aminopeptidase activity of IRAP
is responsible for endosomal aminoterminal trimming of cross-
presented peptides. In addition to the peptide trimming activity,
the most important IRAP features are its interaction with MHC
class I molecules and its presence and role in cell-speciﬁc regu-
lation of IRAP endosomes. The substrate speciﬁcity of IRAP, as
well as the nature of the associated MHC class I molecules will
require further investigation. Speciﬁcally the IRAP preferences
for the length and the internal sequence of peptide substrates
are entirely unknown. Another issue of importance is the extent
to which the different cross-presentation pathways are used by
different DC subsets under various physiologic conditions. Little
is known about how the physiological context; e.g., inﬂamma-
tory cytokines, pathogen-associated danger signals, simultaneous
antibody responses, and CD4+ T cell help modulate intracellular
cross-presentation pathways.
Another issue that should be addressed in the future is a poten-
tial IRAP role in antigen storage by the DCs. van Montfoort et al.
(2009) have shown recently that soluble immune complexes can
be stored by DCs for several days in lysosome-like organelles thus
increasing the potency of cytotoxic T cell priming. Although pre-
liminary results do not suggest a direct presence of IRAP in such
compartments, it cannot be ruled out that IRAP plays a role in
routing immune complexes and/or phagocytosed antigens to such
compartments.
As demonstrated by the study of IRAP trafﬁcking in insulin
responsive cells, there are strong indications that the enzyme is
not only a cargo of cell-speciﬁc storage endosomes but also an
active player in the regulation of their trafﬁcking. Our ongoing
studies suggest that IRAP is required for normal maturation of
phagosomes in BMDCs. We believe that it will be of great interest
to characterize the extracellular stimuli and intracellular signal-
ing pathways that regulate the trafﬁcking of IRAP endosomes
in DCs. Investigation of the cross-presentation pathways used by
thymic DCs may also be of interest. As mentioned above, thymic
CD8+ DCs seem to be the only steady-state DC subpopulation
with a constitutively activated cross-presentation capacity, a fea-
ture that could be important for T cell selection in the thymus and
maintenance of immune tolerance in the periphery.
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